Sun Pharma launches generic Brevipil tablet following patent expiry of the innovator product. (1)
Sun Pharmaceuticals have recently launched an anti–epileptic drug called Brevipil in the market. The company did this launch on 22 February 2021, a day after the expiry of the innovator drug’s patent. The innovator drug for this generic version is called Brivaracetam. This patent of this product expired on 21 February 2021. Read more: Sun Pharma- Popular Brands, Composition, and Pack Details
This innovative drug was manufactured and sold by UCB, a Belgian drug maker, under the BRIVIACT brand name. This Belgian company signed an agreement with Dr. Reddy’s Laboratories in 2018. Per this agreement, Dr. Reddy’s Laboratories gained exclusive rights to sell this drug in India.
Sun Pharma has launched multiple doses and dosage forms of Brevipil tablet in the market. The tablet form is available in 25 mg, 50 mg, 75 mg, and 100 mg strengths. The company has also stated that other dosage forms of Brevipil will soon be made available into the market. These include an injectable ( 10 mg/ml ) and oral solution ( 10 mg/ml ) of the drug.
The innovator drug is currently being sold at around Rs. 106 per tablet across multiple strengths. The generic version that Sun Pharma manufactures is expected to be priced at over Rs. 8 per tablet for 25 mg and Rs. 32 per 100 mg tablet.
Brivaracetam has received the DCGI’s[1] approval as adjuvant therapy to treat partial-onset seizures. This drug is specially prescribed for epileptic patients who are above 16 years of age. This drug has a quick onset of action with good efficacy.
Brevipil tablet uses- Epilepsy is a common neurological disorder that is difficult to manage owing to the social stigma associated with it in India. It is currently estimated that around 5.7 to 6.4 million people are afflicted with this disorder in India. Read about Epilepsy: A marker of Recurrent Seizures
Abbreviation: 1. Drugs Controller General of India
Pingback: Jubilant, Sun, and Lupin initiated products recall > PharmaCampus